Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 41Obesity 9Anovulation 8Infertility 7Insulin Resistance 6Overweight 2Non-alcoholic Fatty Liver Disease 2Hirsutism 2Diabetes, Gestational 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Nodule 1Racism 1Prostatic Neoplasms 1Pregnancy Complications 1Mouth Neoplasms 1Metabolic Syndrome 1Hyperandrogenism 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Dyslipidemias 1Diabetes Mellitus, Type 2 1Breast Cancer Female 1Body Weight 1Amenorrhea 1Acne Vulgaris 1

Interventions

Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination 1Sitagliptin Phosphate 1Metformin 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Body Weight × Metformin × Clear all
NCT02941445 2016-10-21

Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss

University Medical Centre Ljubljana

Phase 4 Completed
24 enrolled

Body Weight, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡